CP and lobular neoplasia: The use of high-dose intravenous CP (0.5–0.75 g/m2 monthly for 6 months) was recommended to be reserved for adult patients with proliferative LN class III/IV showing unfavorable clinical (nephritic urine sediment and impaired renal function with an eGFR between 25 and 80 ml/min/1.73 m2), or histologic (crescents or necrosis in >25% of glomeruli) prognostic factors (21).